Searched for: in-biosketch:true
person:schwar10
Dual inhibition of TNF-α and IL-1β signaling through BIG2 ameliorates osteoarthritis in mouse and primate models
Fu, Wenyu; Liu, Ronghan; Wo, Jin; Liu, Xin; Wang, Shuya; Song, Wenhao; Zhu, Haoran; Cui, Yazhou; Chen, Yuehong; Wang, Chao; Zhang, Lei; Schwarzkopf, Ran; Oh, Irvin; Wiznia, Daniel H; Sun, Guodong; Liu, Chuan-Ju
Osteoarthritis (OA), a leading cause of disability, is characterized by chronic low-grade inflammation and metabolic dysregulation in chondrocytes. TNF-α and IL-1β are key inflammatory drivers in OA pathogenesis, but clinical trials targeting them individually have been unsuccessful, highlighting the potential need for dual-targeting strategies. By screening a US Food and Drug Administration-approved drug library, we identified dabigatran, a thrombin inhibitor, as a potent dual suppressor of TNF-α and IL-1β signaling that restored chondrocyte metabolism. In preclinical OA models, including both mice and cynomolgus macaques, dabigatran attenuated cartilage degeneration, alleviated pain, and improved joint function. To elucidate the molecular mechanisms, we performed biochemical copurification coupled with mass spectrometry, identifying brefeldin A-inhibited guanine nucleotide-exchange protein 2 (BIG2) as a previously unknown dabigatran-binding target. Mechanistically, dabigatran binds to BIG2, promoting BIG2-dependent TNFR1 release to dampen TNF-α signaling while enhancing BIG2-mediated IL-1R1 degradation through the autophagy-lysosome pathway to limit IL-1β effects. These findings establish BIG2-mediated receptor trafficking and membrane dynamics as a regulatory node that concurrently inhibits TNF-α and IL-1β signaling, suggesting this pathway as a potential therapeutic strategy for OA.
PMID: 43013683
ISSN: 1946-6242
CID: 6075827
Dual inhibition of TNF-α and IL-1β signaling through BIG2 ameliorates osteoarthritis in mouse and primate models
Fu, Wenyu; Liu, Ronghan; Wo, Jin; Liu, Xin; Wang, Shuya; Song, Wenhao; Zhu, Haoran; Cui, Yazhou; Chen, Yuehong; Wang, Chao; Zhang, Lei; Schwarzkopf, Ran; Oh, Irvin; Wiznia, Daniel H; Sun, Guodong; Liu, Chuan-Ju
Osteoarthritis (OA), a leading cause of disability, is characterized by chronic low-grade inflammation and metabolic dysregulation in chondrocytes. TNF-α and IL-1β are key inflammatory drivers in OA pathogenesis, but clinical trials targeting them individually have been unsuccessful, highlighting the potential need for dual-targeting strategies. By screening a US Food and Drug Administration-approved drug library, we identified dabigatran, a thrombin inhibitor, as a potent dual suppressor of TNF-α and IL-1β signaling that restored chondrocyte metabolism. In preclinical OA models, including both mice and cynomolgus macaques, dabigatran attenuated cartilage degeneration, alleviated pain, and improved joint function. To elucidate the molecular mechanisms, we performed biochemical copurification coupled with mass spectrometry, identifying brefeldin A-inhibited guanine nucleotide-exchange protein 2 (BIG2) as a previously unknown dabigatran-binding target. Mechanistically, dabigatran binds to BIG2, promoting BIG2-dependent TNFR1 release to dampen TNF-α signaling while enhancing BIG2-mediated IL-1R1 degradation through the autophagy-lysosome pathway to limit IL-1β effects. These findings establish BIG2-mediated receptor trafficking and membrane dynamics as a regulatory node that concurrently inhibits TNF-α and IL-1β signaling, suggesting this pathway as a potential therapeutic strategy for OA.
PMID: 43013683
ISSN: 1946-6242
CID: 6075826
Dual inhibition of TNF-α and IL-1β signaling through BIG2 ameliorates osteoarthritis in mouse and primate models
Fu, Wenyu; Liu, Ronghan; Wo, Jin; Liu, Xin; Wang, Shuya; Song, Wenhao; Zhu, Haoran; Cui, Yazhou; Chen, Yuehong; Wang, Chao; Zhang, Lei; Schwarzkopf, Ran; Oh, Irvin; Wiznia, Daniel H; Sun, Guodong; Liu, Chuan-Ju
Osteoarthritis (OA), a leading cause of disability, is characterized by chronic low-grade inflammation and metabolic dysregulation in chondrocytes. TNF-α and IL-1β are key inflammatory drivers in OA pathogenesis, but clinical trials targeting them individually have been unsuccessful, highlighting the potential need for dual-targeting strategies. By screening a US Food and Drug Administration-approved drug library, we identified dabigatran, a thrombin inhibitor, as a potent dual suppressor of TNF-α and IL-1β signaling that restored chondrocyte metabolism. In preclinical OA models, including both mice and cynomolgus macaques, dabigatran attenuated cartilage degeneration, alleviated pain, and improved joint function. To elucidate the molecular mechanisms, we performed biochemical copurification coupled with mass spectrometry, identifying brefeldin A-inhibited guanine nucleotide-exchange protein 2 (BIG2) as a previously unknown dabigatran-binding target. Mechanistically, dabigatran binds to BIG2, promoting BIG2-dependent TNFR1 release to dampen TNF-α signaling while enhancing BIG2-mediated IL-1R1 degradation through the autophagy-lysosome pathway to limit IL-1β effects. These findings establish BIG2-mediated receptor trafficking and membrane dynamics as a regulatory node that concurrently inhibits TNF-α and IL-1β signaling, suggesting this pathway as a potential therapeutic strategy for OA.
PMID: 43013683
ISSN: 1946-6242
CID: 6075825
Patient-specific management in high-risk revision total hip arthroplasty: mid-term outcomes of a next-generation constrained acetabular liner
Khury, Farouk; Luebbering, Blaine; Ruff, Garrett; Bahlouli, Laith; Sarfraz, Anzar; Schwarzkopf, Ran; Aggarwal, Vinay K
BACKGROUND:Managing recurrent instability in revision total hip arthroplasty (rTHA) requires a personalized approach, as traditional constrained liners often yield suboptimal results due to locking-mechanism failure and limited impingement-free range of motion. This study aimed to evaluate the mid-term clinical outcomes of a novel constrained acetabular liner (CAL) when utilized as a patient-specific solution for a high-risk cohort undergoing complex rTHA. By tailoring the constraint to individual biomechanical deficits, this next-generation device seeks to mitigate historic failure modes. METHODS:We retrospectively reviewed 32 patients who underwent 37 rTHA procedures with a next-generation CAL at a single urban academic center between March 2017 and October 2023. Average follow-up was 4.7 years (range, 0.3 to 9.7 years). The most common indication for rTHA was instability (70.3%), followed by infection (16.2%), aseptic loosening (10.8%), and polyethylene wear (2.7%). Just over one third of patients (37.5%) had undergone a prior revision. Preoperative constructs included fixed-bearing (37.8%), dual-mobility (32.4%), CAL (24.3%), static spacer (2.7%), and hemiarthroplasty (2.7%). RESULTS:In most procedures (70.3%), the CAL was implanted into a pre-existing acetabular cup, whereas 29.7% involved both cup and liner revision. Following rTHA, no cases of implant wear, breakage, acetabular cup aseptic loosening, or periprosthetic fracture were observed. Six patients (18.8%) underwent a total of sixteen subsequent reoperations after CAL implantation-10 for instability and 6 for infection. Among instability-related reoperations, 4 involved revision to a new next-generation CAL. Survivorship free from all-cause reoperation was 83.8% at one year and 72.6% at latest follow-up. CONCLUSIONS:This study demonstrates favorable mid-term clinical outcomes and reoperation-free survivorship following complex revision THA using a novel constrained acetabular liner system. For patient cohorts suffering from severe recurrent dislocation, this next-generation CAL provides an effective, tailored tool in the surgical armamentarium by adapting to unique patient anatomy and soft-tissue compromises. Further research with larger sample sizes and extended follow-up is needed to assess long-term durability.
PMCID:13683562
PMID: 42902017
ISSN: 1434-3916
CID: 6074879
Analysis of serological markers and synovial fluid cytology in aseptic revision total knee arthroplasty
Khury, Farouk; Zhong, Jack; Ruff, Garrett; Sarfraz, Anzar; Bahlouli, Laith; Aggarwal, Vinay K; Schwarzkopf, Ran
BACKGROUND AND AIM/OBJECTIVE:Recent studies examining synovial fluid analysis to differentiate causes for aseptic revision total knee arthroplasty (rTKA) were limited to aseptic loosening and instability. This study aims to establish specific serological and synovial profiles for various rTKA etiologies. METHODS:We retrospectively reviewed patients who underwent aseptic rTKA at a single academic institution between 2012 and 2023. Inclusion required complete serum inflammatory markers (erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP)) and synovial fluid differentials within three months pre-operatively. Periprosthetic joint infections were strictly excluded utilizing the 2018 International Consensus Meeting criteria. In total, 156 patients were included and stratified into five aseptic etiologies: aseptic loosening (50.6%), instability (28.2%), arthrofibrosis (16.7%), liner wear (2.6%), and component malposition (1.9%). Serological markers were evaluated utilizing a multivariate general linear model adjusting for patient demographics, while synovial markers were assessed via Welch's Analysis of Variance (ANOVA) and Games-Howell post-hoc testing. RESULTS:Multivariate analysis demonstrated that the underlying rTKA indication was not a significant independent predictor of elevated ESR (P = 0.661) or CRP (P = 0.947). Welch's ANOVA revealed significant differences in the percentage of synovial monocytes (P < 0.001) and lymphocytes (P = 0.010), alongside the polymorphonuclear cells/monocyte (P = 0.030) and lymphocyte/monocyte (P = 0.005) ratios. Games-Howell post-hoc testing demonstrated the tibial liner wear group exhibited significantly higher monocyte percentages, paired with lower lymphocyte percentages and cellular ratios, compared to other aseptic etiologies. CONCLUSIONS:This study revealed that routine systemic inflammatory markers and standard synovial fluid cell counts do not significantly vary among the common etiologies of aseptic rTKA. Nonetheless, tibial polyethylene liner wear appears to elicit an exploratory, monocyte-predominant and lymphocyte-depleted local macrophage response that is absent in other mechanisms of aseptic failure. Further research with larger cohorts is warranted to validate this association and explore its potential as a diagnostic tool.
PMCID:13683490
PMID: 42902091
ISSN: 1434-3916
CID: 6074880
Early Revision Rates and Clinical Outcomes of Two Cementless Cruciate-Retaining Total Knee Arthroplasty Designs at Two-Year Follow-Up: A Propensity Score-Adjusted Comparative Analysis
Schaffer, Olivia; Kennedy, Mitchell; Li, Andrew; Novikov, David; Meftah, Morteza; Rozell, Joshua C; Schwarzkopf, Ran
PMCID:13706768
PMID: 42942450
ISSN: 1648-9144
CID: 6074744
Intraprosthetic dislocation in modular dual-mobility: does the company matter? A systematic review and meta-analysis
Shanaa, Jean; Stoebner, Jacob; Di Pauli von Treuheim, Theodor; Schwarzkopf, Ran; Cohen-Rosenblum, Anna; Aggarwal, Vinay K
INTRODUCTION/BACKGROUND:Intraprosthetic dislocation (IPD) is a rare but potentially catastrophic complication of dual-mobility (DM) implants, defined by dissociation of the inner femoral head from the polyethylene liner. Modular dual-mobility (MDM) designs were introduced to improve intraoperative flexibility and expand indications for DM technology. However, increasing reports of IPD have raised concerns that implant design and manufacturing differences may influence risk. The true incidence of IPD across MDM manufacturers remains unclear. METHODS:A systematic search of PubMed, Embase, and Web of Science was performed. Studies reporting IPD incidence and stratified outcomes by implant manufacturer were included. A random-effects proportion meta-analysis was conducted to estimate pooled IPD incidence and revision rates overall and by manufacturer. RESULTS:Of 523 identified articles, 32 met inclusion criteria, representing 3996 implants (2711 primary; 1285 revision). Mean follow-up was 3.48 years and mean age was 67.48 years. The overall IPD incidence was 0.38% (15/3996), with a pooled estimate of 0.1% (95% CI, 0-0.5%). Stratified analyses showed IPD rates of 0% for Stryker (95% CI, 0-0.7%), 0% for Zimmer (95% CI, 0-100%), and 0% for Groupe Lépine (95% CI, 0-100%). Reoperation rates were 1.4% (95% CI, 0.9-2.1%) in primary and 8.3% (95% CI, 6.0-11.3%) in revision THA. CONCLUSIONS:The incidence of IPD in MDM implants is low, with pooled rates remaining below 1%. Revision rates were modest and consistent with published data on complex hip arthroplasty. No significant differences between manufacturers were detected, though findings are limited by the small number of non-Stryker implants reported. These findings suggest that MDM designs appear safe with overall low numbers of IPD-related complications, however, larger registry-based studies are needed to better define potential design-related differences in IPD risk.
PMID: 42770469
ISSN: 1724-6067
CID: 6073510
Glucagon-like Peptide-1 Receptor Agonist Use May Reduce Disease Activity and Progression in Osteoarthritis and Inflammatory Arthritis
Trudeau, Maxwell; Schaffer, Olivia; Schwarzkopf, Ran
Obesity, metabolic syndrome, and type 2 diabetes mellitus contribute to osteoarthritis (OA) through adipokine signaling, systemic inflammation, oxidative stress, and insulin resistance, affecting both weight-bearing and non-weight-bearing joints. Glucagon-like peptide-1 receptor agonists have rapidly expanded in use and promises musculoskeletal benefits beyond weight loss. Preclinical studies demonstrate anti-inflammatory, analgesic, and chondroprotective effects, including reduced cytokine activity and cartilage matrix degradation. Randomized trials in knee OA show significant weight loss with modest improvements in pain and function, while observational data suggest possible cartilage preservation and reduced surgical rates, though results are mixed. Evidence in inflammatory arthritis is promising but limited.
PMID: 42692567
ISSN: 1558-1373
CID: 6072012
Midterm Outcomes of Revision Total Hip Arthroplasty With Cementation of a Monoblock Dual-Mobility Bearing Cup in a Porous Revision Acetabular Shell
Antonioli, Sophia S; Ruff, Garrett; Khury, Farouk; Aggarwal, Vinay K; Rozell, Joshua C; Schwarzkopf, Ran
BACKGROUND/UNASSIGNED:Dual-mobility (DM) articulations and porous acetabular shells are increasingly used to address instability and mechanical loosening in revision total hip arthroplasty (rTHA). However, reports of longer-term outcomes with the new generation of DM articulations and porous shells remain limited. Our study reports the use and outcomes of a cemented monoblock DM cup in a fully porous acetabular shell in complex rTHA cases with midterm follow-up. METHODS/UNASSIGNED:A retrospective study was conducted of rTHAs with an acetabular construct of a monoblock DM cup cemented into a fully porous acetabular shell between June 2016 and December 2019. Baseline demographics, operative information, and outcomes were gathered for a total of 55 patients. Ten patients died, and 4 were lost to follow-up at 5 years; 41 patients were included in the analysis of midterm outcomes. RESULTS/UNASSIGNED:The most common indications for rTHA were acetabular component loosening (43.6%), periprosthetic joint infection (PJI) (16.4%), dislocation (12.7%), and periprosthetic fracture (9.1%). Preoperative acetabular bone loss assessment found 43.7% type IIA, 9.1% IIB, 20.0% IIC, 23.6% IIIA, and 3.6% IIIB according to the Paprosky classification. Six patients (10.9%) were readmitted within 90 days for PJI (n = 5; 9.1%) or dislocation (n = 1; 1.8%). Four patients (9.8%) required revision of the construct: 2 for PJI, 1 case of instability, and 1 case of aseptic loosening of the acetabular component with significant acetabular bone loss. The average time to revision was 1.4 years (range, 0.1-3.8 years). The mean follow-up period was 6.4 years (range, 4.7-8.2 years). The cup in cup construct had an all-cause survivorship of 95.8% and 90.0% at 1 and 5 years, respectively, and aseptic survivorship rates of 97.9% and 94.7% at 1 and 5 years, respectively. CONCLUSIONS/UNASSIGNED:This cohort of 55 patients who underwent complex rTHA with a monoblock DM cup cemented into a porous acetabular shell exhibited reliable fixation and low revision rates. In complex revision cases where instability and inadequate fixation are concerns, these outcomes support continued consideration and use of this unique and durable construct.
PMCID:13486779
PMID: 42621099
ISSN: 2352-3441
CID: 6071489
The Impact of Patellar Resurfacing on Costs and Outcomes in Primary Total Knee Arthroplasty
Sarfraz, Anzar; Ruff, Garrett; Schaffler, Benjamin; Khury, Farouk; Bosco, Joseph; Schwarzkopf, Ran; Aggarwal, Vinay K
INTRODUCTION/BACKGROUND:Patellar resurfacing in primary total knee arthroplasty (TKA) has been debated for decades. This study aimed to evaluate cost-effectiveness and clinical outcomes of patellar resurfacing in modern TKA at a high-volume arthroplasty center. METHODS:A retrospective study was conducted on 4,534 patients who underwent unilateral, elective, primary TKA from 2021 to 2024 at an urban academic institute. Patients were stratified by patellar resurfacing: resurfaced (n=3,753) or not (n=781). Baseline characteristics, operative costs [implants, anesthesia, operating room time], and postoperative outcomes (revision incidence) were collected. The median follow up was 2.0 years (1.0- 4.8). The individual cost of patellar component was adjusted for implant manufacturer and cementation out of total implant cost. Multivariable regression analysis determined added operating room time (ORT) due to patellar resurfacing, controlling for body-mass index, usage of robotics, navigation and cementation. Relative costs of added ORT and the patellar component were compared to total implant and procedure costs of patellar-resurfacing operations. RESULTS:The patellar component accounted for an average of 7.9% of the total implant cost in patellar-resurfacing operations. Patellar-resurfacing operations had longer operative times (112.2 vs. 105.4 minutes, P<0.001), and multivariable regression determined patellar resurfacing is associated with an added 6.3 minutes of total ORT (P<0.001). The patellar component implant cost and the cost of added ORT due to resurfacing accounted for 4.5% of the total procedure cost in resurfaced group. Resurfaced group had an overall 5% higher total operative cost than the non-resurfaced group. No differences existed in length of stay (LOS), discharge disposition, or all-cause and patella-specific revision incidence. CONCLUSION/CONCLUSIONS:We found that patellar resurfacing was associated with longer operative times and greater implant and procedure costs, although there was no effect on LOS, discharge disposition, or all-cause and patella-specific revision incidence. Ultimately, the decision to resurface the patella in primary TKA should be based on patient-specific indications and clinical judgment. However, it is important to consider the additional cost associated with this procedure.
PMID: 42612981
ISSN: 1938-2480
CID: 6071456